|Life Extension Update Exclusive |
Scientists demonstrate inflammation’s effect on glucose levels
The Therapeutic Approaches to Obesity and Related Disorders conference held in Washington DC was the site of a presentation on July 22 by scientists from Galileo Pharmaceuticals concerning the demonstration of a direct relationship between inflammation and glucose levels. The finding adds to a growing body of information linking inflammation with a number of diseases and age-related conditions.
Using a mouse model of diabetes, Galileo researchers administered a 5-lipoxygenase and 15-lipoxygenase inhibitor and measured the animals’ blood glucose and insulin levels. Lipoxygenases are enzymes that are involved in the production of leukotrienes, which are mediators of inflammation. Five and 15-lipoxygenase have been implicated in asthma, arthritis, atherosclerosis, diabetes, osteoporosis, and cancer. The scientists observed a 20 percent reduction in the animals’ blood glucose levels while insulin levels remained the same--results that are comparable to those of a leading antidiabetic drug
Lloyd M. Kunimoto, who is the president and chief executive officer of Galileo Pharmaceuticals, stated, "Metabolic disease is a health concern of near-epidemic proportions, particularly in the US. We are encouraged by our initial study, which confirms the role of inflammation in the regulation of carbohydrate and lipid metabolism. “
"There is increasing scientific evidence that suggests that inflammation is a key component of onset and progression of metabolic disease,” added Galileo Pharmaceuticals’ chief scientific officer and executive vice president of research and development, David Liebowitz, MD, PhD. “We have already identified potent lipoxygenase inhibitors that have shown activity in preclinical animal models of diabetes and are evaluating more potent and pharmacologically optimized leads in appropriate animal models."